IMPEDIMED LIMITED — Director's Dealing 2024

Jan 9, 2024

==> picture [131 x 24] intentionally omitted <==

10 January 2024

ASX ANNOUNCEMENT

Appointment of Executive Director

ImpediMed Limited (ASX.IPD) ( ImpediMed or Company ) advises that, as indicated in the Company’s announcement of 20 November 2023, Dr Parmjot Bains commenced as Managing Director and Chief Executive Officer in an interim capacity on Monday, 08 January 2024.

Attached is the Initial Director’s Interest Notice for Dr Bains.

Approved for release by the Company Secretary, Ms Leanne Ralph.

Contact Details

Investor Relations Contact:

Hannah Howlett WE Communications

T: +61 450 648 064

• E: hhowlett@we-worldwide.com

• E: investorrelations@impedimed.com

About ImpediMed

Founded and headquartered in Brisbane, Australia with US and European operations, ImpediMed is a medical technology company that uses bioimpedance spectroscopy (BIS) technology to generate powerful data to maximise patient health. ImpediMed produces the SOZO[®] Digital Health Platform, which is FDAcleared, CE-marked, and ARTG-listed for multiple indications, including lymphoedema, heart failure, and protein calorie malnutrition and sold in select markets globally.

In March 2023, the NCCN Clinical Practice Guidelines In Oncology (NCCN Guidelines[®] ) for Survivorship were updated and reference bioimpedance spectroscopy as the recommended objective tool to screen atrisk cancer patients for early signs of lymphoedema. With the SOZO Digital Health Platform and L-Dex[®] , ImpediMed is the only company to offer FDA-cleared technology that uses bioimpedance spectroscopy for the clinical assessment of lymphoedema. The connected digital health platform and large, attractive cancerrelated lymphoedema market present an opportunity for continued strong growth through ImpediMed’s SaaS subscription-based business.

For more information, visit www.impedimed.com.

==> picture [131 x 24] intentionally omitted <==

Forward-Looking Statements

This announcement contains or may contain forward-looking statements that are based on management’s beliefs, assumptions and expectations and on information currently available to management.

All statements that address operating performance, events or developments that we expect or anticipate will occur in the future are forward-looking statements, including without limitation our expectations with respect to our ability to expand sales and market acceptance in the US and Australia including our estimates of potential revenues, costs, profitability and financial performance; our ability to develop and commercialise new products including our ability to obtain reimbursement for our products; our expectations with respect to our clinical trials, including enrolment in or completion of our clinical trials and our associated regulatory submissions and approvals; our expectations with respect to the integrity or capabilities of our intellectual property position.

Management believes that these forward-looking statements are reasonable as and when made. You should not place undue reliance on forward-looking statements because they speak only as of the date when made. ImpediMed does not assume any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. ImpediMed may not actually achieve the plans, projections or expectations disclosed in forward-looking statements. Actual results, developments or events could differ materially from those disclosed in the forward-looking statements.

Appendix 3X Initial Director’s Interest Notice

Rule 3.19A.1

Appendix 3X

Initial Director’s Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX’s property and may be made public.

Introduced 30/9/2001.

Name of entity: ImpediMed Limited

ABN/ASRN: 65 089 705 144

We (the entity) give ASX the following information under listing rule 3.19A.1 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Dr Parmjot Bains
Date of appointment	08 January 2024

Part 1 - Director’s relevant interests in securities of which the director is the registered holder

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of “notifiable interest of a director” should be disclosed in this part.

Number & class of securities

21,673 fully paid ordinary shares

• See chapter 19 for defined terms.

Appendix 3X Page 1

Appendix 3X Initial Director’s Interest Notice

Part 2 – Director’s relevant interests in securities of which the director is not the registered holder

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

==> picture [401 x 128] intentionally omitted <==

----- Start of picture text -----

Name of holder & nature of Number & class of Securities
interest
Note: Provide details of the circumstances giving rise to
the relevant interest.
Nil
----- End of picture text -----

Part 3 – Director’s interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of “notifiable interest of a director” should be disclosed in this part.

Detail of contract	Contract for the role of Interim Managing Director and CEO, the details of which were included in the ASX release on 20 November 2023
Nature of interest
Name of registered holder (if issued securities)
No. and class of securities to which interest relates

Date of Notice: 10 January 2024

• See chapter 19 for defined terms.

Appendix 3X Page 2